Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)

Table 3 Patient reported outcomes and quality of life

	EORTC QLQC30 or PedsQL	Hesitancy scale	PRO CTCAE	Toxicity^a
Vaccine dose 1 (− 7)	X	X
D7 (± 1) post dose 1	X		X
Vaccine dose 2	X
D7 (± 1) post dose 2	X		X
3 M post dose 2	X			X

D day, M month, EORTC QLQ European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, PRO CTCAE Patient Reported Outcomes Common Terminology Criteria for Adverse Events
^aMedical record review

ISSN: 1471-2334